- Home
- UDMY vs ABUS Comparison
UDMY vs ABUS Comparison
Compare UDMY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- ABUS
- Stock Information
- Founded
- UDMY 2009
- ABUS 2005
- Country
- UDMY United States
- ABUS United States
- Employees
- UDMY N/A
- ABUS N/A
- Industry
- UDMY Other Consumer Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- UDMY Real Estate
- ABUS Health Care
- Exchange
- UDMY Nasdaq
- ABUS Nasdaq
- Market Cap
- UDMY 1.0B
- ABUS 906.7M
- IPO Year
- UDMY 2021
- ABUS N/A
- Fundamental
- Price
- UDMY $5.42
- ABUS $4.40
- Analyst Decision
- UDMY Buy
- ABUS Strong Buy
- Analyst Count
- UDMY 10
- ABUS 2
- Target Price
- UDMY $9.67
- ABUS $5.00
- AVG Volume (30 Days)
- UDMY 2.2M
- ABUS 951.5K
- Earning Date
- UDMY 10-29-2025
- ABUS 11-06-2025
- Dividend Yield
- UDMY N/A
- ABUS N/A
- EPS Growth
- UDMY N/A
- ABUS N/A
- EPS
- UDMY N/A
- ABUS N/A
- Revenue
- UDMY $795,801,000.00
- ABUS $15,416,000.00
- Revenue This Year
- UDMY $2.58
- ABUS $138.02
- Revenue Next Year
- UDMY $4.19
- ABUS N/A
- P/E Ratio
- UDMY N/A
- ABUS N/A
- Revenue Growth
- UDMY 2.53
- ABUS 53.23
- 52 Week Low
- UDMY $5.33
- ABUS $2.71
- 52 Week High
- UDMY $10.61
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- UDMY 29.38
- ABUS 48.44
- Support Level
- UDMY $5.34
- ABUS $4.26
- Resistance Level
- UDMY $5.86
- ABUS $4.95
- Average True Range (ATR)
- UDMY 0.27
- ABUS 0.21
- MACD
- UDMY -0.16
- ABUS -0.01
- Stochastic Oscillator
- UDMY 4.02
- ABUS 20.44
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.